Literature DB >> 8611716

Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.

R Bhatia1, J B McCarthy, C M Verfaillie.   

Abstract

Chronic myelogenous leukemia (CML) progenitors show decreased adhesion to stroma and fibronectin (FN) through beta 1 integrin receptors. We have previously shown that interferon-alpha (IFN-alpha) restores beta 1 integrin-mediated adhesion of CML progenitors to stroma. Because beta1 integrins transmit proliferation inhibitory signals from the microenvironment to normal hematopoietic progenitors, we hypothesized that decreased integrin-mediated adhesion of CML progenitors contributes to their continuous proliferation when in contact with stroma and that IFN-alpha treatment, by restoring integrin-mediated adhesion, also restores integrin-mediated microenvironmental inhibition of CML progenitor proliferation. We show here that, in contrast to normal colony-forming cells (CFC), the percentage of malignant CML CFC in S-phase was not significantly reduced following coculture with stromal layers. However, IFN-alpha treatment resulted in a significant reduction in the proliferation of CML CFC on coculture with stroma. This effect was not because of a direct antiproliferative effect of IFN-alpha on CML CFC because the proliferation of IFN-alpha treated CML CFC kept in suspension culture was not reduced. We examined the role of restored signaling through beta 1 integrin receptors in IFN-alpha induced inhibition of CML progenitors in two sets of experiment. In the first set of experiments, we demonstrated that proliferation of IFN-alpha-treated CML CFC, but not untreated CML CFC, was significantly reduced following coculture with 33/66-kD and 75-kD FN fragments, recognized by alpha 4 beta 1 and alpha 5 beta 1 integrins respectively. In a second set of experiments, we demonstrate that direct stimulation of integrin receptors by crosslinking with blocking antibodies to alpha 4, alpha 5, and beta 1 integrins and secondary goat antimouse antibodies resulted in significant reduction in proliferation of normal and IFN-alpha treated CML progenitors but not untreated CML CFC. These studies indicate that CML hematopoietic progenitors are unresponsive to beta 1-integrin mediated proliferation inhibition and that IFN-alpha not only restores beta 1 integrin-mediated adhesion but also beta1-mediated microenvironmental inhibition of CML progenitor proliferation. These observations may explain, at least in part, the therapeutic efficacy of IFN-alpha in CML.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611716

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.

Authors:  Francesca Palandri; Fausto Castagnetti; Ilaria Iacobucci; Giovanni Martinelli; Marilina Amabile; Gabriele Gugliotta; Angela Poerio; Nicoletta Testoni; Massimo Breccia; Monica Bocchia; Monica Crugnola; Giovanna Rege-Cambrin; Bruno Martino; Ivana Pierri; Franca Radaelli; Giorgina Specchia; Fabrizio Pane; Giuseppe Saglio; Gianantonio Rosti; Michele Baccarani
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

Review 2.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

3.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

5.  Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

Authors:  Daniela S Krause; Katherine Lazarides; Juliana B Lewis; Ulrich H von Andrian; Richard A Van Etten
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

6.  Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.

Authors:  A Krämer; S Hörner; A Willer; S Fruehauf; A Hochhaus; M Hallek; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.

Authors:  Y Jiang; R C Zhao; C M Verfaillie
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 9.  Tumor reversion: correction of malignant behavior by microenvironmental cues.

Authors:  Paraic A Kenny; Mina J Bissell
Journal:  Int J Cancer       Date:  2003-12-10       Impact factor: 7.396

10.  Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high-affinity beta1 integrins as coreceptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells.

Authors:  Kirsten A K Weigel-Van Aken
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.